Researchers continue to excited about Retatrutide , a novel dual agonist showing promising data in initial trials for size reduction . It acts by modulating several pathways : GLP-1 and GIP, that , when engaged , help influence cravings and boost energy expenditure . Initial reports indicate substantial body reduction and potential improvements for